Abstract
Approximately 20% of patients who are FMR1 premutation carriers present with premature ovarian failure (POF) compared to 1% of the general population (Gallagher, 2012). The risk of POF in female carriers appears to increase with increasing CGG repeat size up to 99, after which the risk plateaus or decreases for women with repeat size>100 (Uzeil, 1999; Wittenberger, 2007). Recently, Anti-Mullerian hormone (AMH) has been evaluated as a novel clinical marker of follicular reserve in the prediction of quantitative oocyte response (La Marca, 2010).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
